Enzymotec (Enzymotec) Change In Receivables : $0.95 Mil (TTM As of Sep. 2017)

View and export this data going back to 2013. Start your Free Trial

What is Enzymotec Change In Receivables?

Enzymotec's change in receivables for the quarter that ended in Sep. 2017 was $0.36 Mil. It means Enzymotec's Accounts Receivable declined by $0.36 Mil from Jun. 2017 to Sep. 2017 .

Enzymotec's change in receivables for the fiscal year that ended in Dec. 2016 was $5.60 Mil. It means Enzymotec's Accounts Receivable declined by $5.60 Mil from Dec. 2015 to Dec. 2016 .

Enzymotec's Accounts Receivable for the quarter that ended in Sep. 2017 was $10.52 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Enzymotec's Days Sales Outstanding for the three months ended in Sep. 2017 was 70.24.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Enzymotec's liquidation value for the three months ended in Sep. 2017 was $43.37 Mil.

Enzymotec Change In Receivables Historical Data

The historical data trend for Enzymotec's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzymotec Change In Receivables Chart

Enzymotec Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Change In Receivables

Get a 7-Day Free Trial

-3.81

-6.97

5.30

-0.88

5.60

Enzymotec Quarterly Data
	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17
Change In Receivables	Get a 7-Day Free Trial															0.86	2.98	-1.39	-1.01	0.36

Enzymotec Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.95 Mil.

Enzymotec (NAS:ENZY) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Enzymotec's Days Sales Outstanding for the quarter that ended in Sep. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	10.524	/	13.672	*	91
=	70.24

2. In Ben Graham's calculation of liquidation value, Enzymotec's accounts receivable are only considered to be worth 75% of book value:

Enzymotec's liquidation value for the quarter that ended in Sep. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	39.713	-	16.112	+	0.75 * 10.524	+	0.5 * 23.751
=	43.37

Enzymotec Change In Receivables Related Terms

Thank you for viewing the detailed overview of Enzymotec's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzymotec (Enzymotec) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enzymotec Ltd (NAS:ENZY) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.enzymotec.com

Enzymotec Ltd is nutritional and food ingredients company. It develops and manufactures nutritional ingredients and medical foods based on proprietary technologies. Its product portfolio includes Infat, K-Real, Enzy PS solutions, Vayacog, Vayarin and Vayaroll. The company has Nutrition and Vaya Pharma reportable segments. It derives majority of its revenues from Nutrition segment. The firm mainly operates in America, Europe, Australia, Asia, and Israel.

Enzymotec (Enzymotec) Headlines

From GuruFocus

Tiger Management Founder Julian Robertson Ups Stake in Enzymotec

By Kyle Ferguson Kyle Ferguson • 12-07-2015

Julian Robertson Adds to Multiple Positions in 3rd quarter

By Tiziano Frateschi Tiziano Frateschi • 12-20-2016

Julian Robertson Cuts Half of Stake in Paulson-Backed Company

By Holly LaFon Holly LaFon • 07-01-2016